Atezolizumab in combination with carboplatin and etoposide for heavily treated small cell lung cancer

Atezolizumab was the first immune checkpoint inhibitor (ICI) to be introduced as a first‐line treatment option for extensive‐stage small cell lung cancer (ES‐SCLC), in combination with carboplatin and etoposide (CE) chemotherapy. However, SCLC treatment options after progression to first‐line chemot...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Thorac Cancer
Autori principali: Kataoka, Nobutaka, Kunimatsu, Yusuke, Tachibana, Yusuke, Sugimoto, Takumi, Sato, Izumi, Tani, Nozomi, Ogura, Yuri, Hirose, Kazuki, Takeda, Takayuki
Natura: Artigo
Lingua:Inglês
Pubblicazione: John Wiley & Sons Australia, Ltd 2020
Soggetti:
Case Reports
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7471014/
https://ncbi.nlm.nih.gov/pubmed/32706170
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.13588
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi